[ad_1]
Bag?road, Denmark, 26 June 2021 – According to data provided by Novo Nordisk today, an investigational 2.0 mg dose of Ozempic® (semaglutide) provides statistically significant and superior blood glucose (HbA1C) Compared to Ozempic® 1.0 mg1These data are the results of the SUSTAIN FORTE trial, a phase 3b, 40-week, efficacy and safety trial comparing semaglutide 2.0 mg once a week with Ozempic® Among 961 adults with type 2 diabetes who needed an additional blood sugar reduction, 1.0 mg was used as an additive to metformin, with or without sulfonylureas. The result is 81Yingshi American Diabetes Association (ADA) Annual Scientific Meeting1, 2 And the main results are being published The Lancet Diabetes and Endocrinology.
The trial reached the primary endpoint, which was an increase in mean baseline HbA1c in patients receiving 2.0 mg of semaglutide once a week1C 8.9% of people proved that HbA1c was reduced by 2.2%, which was statistically significant and superior1C 1.9% reduction compared to Ozempic® 1.0 mg after 40 weeks, taken as expected*1.
A further post-event subgroup analysis presented at the conference showed that semaglutide 2.0 mg showed greater blood glucose reduction at 40 weeks compared to Ozempic® 1.0 mg, across baseline HbA1C Subgroup (Table 1) 2.
“Some people with type 2 diabetes need additional support to reach their blood sugar goals,” said Juan Pablo Frias, PhD, medical director of the Los Angeles National Institute and principal investigator of SUSTAIN FORTE. “The decrease in blood glucose observed with semaglutide 2.0 mg indicates a higher dose of Ozempic® May provide individuals with the opportunity to further improve diabetes control, and its tolerance is comparable to Ozempic® 1.0 mg. “
Starting from an average baseline weight of 99.3 kg, semaglutide 2.0 mg showed a statistically significant weight loss of 6.9 kg compared to Ozempic 1.0 kg of 6.0 kg®*. Further post-hoc analysis across the baseline BMI subgroup showed that semaglutide 2.0 mg had a non-significantly greater weight loss compared to the 1.0 mg dose (Table 1).
In the main analysis, the incidence of adverse events (AE) at the two doses was similar, including gastrointestinal events (nausea, diarrhea, and vomiting) that crossed baseline HbA11C And BMI subgroups1,2This is consistent with the AE seen in the GLP-1 RA category.
“Ozempic® Martin Lange, executive vice president of Novo Nordisk, said that he has helped millions of type 2 diabetes patients around the world reduce blood sugar, reduced the risk of major cardiovascular events in adults with cardiovascular diseases, and proved that some patients have lost weight. “For nearly a century, our mission has been to promote diabetes treatment and innovative changes to improve the lives of diabetic patients. These data show us that using a higher dose of 2.0 mg of semaglutide, we can help more future Lower HbA in type 2 diabetic patients who control blood sugar1c.”
| postal——temporary secondgroup A kindanalysis phosphorusedge electronicEndpoint: CHang in HemoglobinA kind1C2 |
postal——temporary secondgroup A kindanalysis secondMinor electronicEndpoint: CHang on weight2 |
|||||||
The full story on Benzinga.com
[ad_2]
Source link
